For people predicting that Oncosec would trade at book value, we got pretty close to it today. Rediculous in my opinion. At AACR Oncosec will disclose not only pre-clinical data for the multi-gene construct but also the target indication for this new product which could be market disruptive. Not surprised at all that the stock is under pressure right now while we wait for more details. I believe this is the buying opportunity of a lifetime.
News 
Market Data 
Discover 
